Longer-term treatment with immunosuppressants may halve the risk of relapse, or of symptoms returning, in neuromyelitis optica spectrum disorder (NMOSD), a study in China found. When taken non-stop for up to five years, such treatment reduced the risk of relapse in NMOSD patients, with a mild rebound when immunosuppressants…
immunosuppression
Giving immunosuppressive therapy to patients with antibodies against aquaporin-4 protein (AQP4) and optic neuritis but no symptoms may help resolve observed lesions and prevent a relapse of neuromyelitis optica spectrum disorder (NMOSD), a case report suggests. The case study, “Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder,” was…
Rituximab may be a more effective immunosuppressive therapy for preventing a first relapse in people with neuromyelitis optica spectrum disorder (NMOSD) than mycophenolate mofetil (MMF), a new meta-analysis found. The anti-CD20 antibody rituximab, commonly used off-label in NMOSD, also appears to work better than azathioprine, though the results failed…
As the COVID-19 pandemic rages on, many families are concerned about the holidays. I’m trying to approach the season with patience, but as someone with neuromyelitis optica (NMO), I’m also tired, frustrated, and scared. Living with this disease and taking immunosuppressants means I’m at a higher risk of becoming…
Recent Posts
- Brain, nerve damage link to relapse, disability in AQP4-related NMOSD
- With NMOSD, my to-do lists now include staying well, as well as staying busy
- Advocates join forces to create, celebrate World NMOSD Awareness Day
- With a compromised immune system, constant infections are my nemesis
- Approved NMOSD therapies better than rituximab at preventing relapses